Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma

Table 1 Clinical data for patients in the nedaplatin group and the cisplatin group

	NDP group	DDP group	χ2	P value
Case	34	34
Gender
Male	18	20	0.239	0.625
Female	16	14
Age
Range	27-72	26-70
Median	54	53
Clinical stage (Union for International Cancer Control )
IIa	4	6	0.478	0.787
IIb	10	9
III	20	19
Tumor length
< 5 cm	14	17	0.534	0.465
≥ 5 cm	20	17
Cervical	5	3
Location in the esophagus
Upper	12	15	1.130	0.770
Middle	14	12
Lower	3	4
Medullary	20	22
Fungoid	6	5
Pathology
Ulcer type	5	5	0.386	0.943
Sclerotic type	3	2
General status (Eastern Cooperative Oncology Group score)
0-1	24	21	0.591	0.442
2	10	13

NDP: Nedaplatin; DDP: Cisplatin.

Table 2 Short-term response in the two groups n (%)

Group	n	CR	PR	SD	PD	RR	χ2	P value
NDP group	33	6 (18.2)	24 (72.7)	3 (9.1)	0 (0)	90.9%	1.276	0.528
DDP group	32	5 (15.6)	21 (65.6)	6 (18.8)	0 (0)	81.3%

RR = (PR+CR)/n. NDP: Nedaplatin; DDP: Cisplatin; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; RR: Response rate.

Table 3 Acute adverse events in the two groups

Acute adverse reactions	NDP group (n = 34)						DDP group (n = 34)						χ2	P value
	0	I	II	III	IV	Incidence	0	I	II	III	IV	Incidence
Hemoglobin	14	9	5	5	1	58.80%	16	8	5	4	1	52.90%	0.303	0.990
Leukopenia	13	8	7	6	0	61.80%	15	8	6	4	1	55.90%	1.62	0.805
Platelet	15	7	6	5	1	55.90%	20	4	7	3	0	41.20%	3.109	0.540
Bilirubin	29	4	1	0	0	14.70%	30	3	1	0	0	11.80%	0.16	0.923
Transaminase	25	8	1	0	0	26.50%	27	7	0	0	0	20.60%	1.144	0.565
Urea nitrogen	30	4	0	0	0	11.80%	29	3	2	0	0	14.70%	2.16	0.340
Creatinine	31	2	1	0	0	8.80%	21	9	3	1	0	38.20%	8.378	0.039
Nausea	28	4	1	1	0	17.60%	17	7	6	4	0	50.00%	8.878	0.031
Vomiting	30	2	1	1	0	11.80%	18	6	4	6	0	47.10%	10.371	0.016
Esophagitis	8	18	7	1	0	76.50%	4	19	9	1	1	88.20%	2.61	0.625
Pneumonia	18	14	2	0	0	47.10%	12	17	4	1	0	64.70%	3.157	0.368

NDP: Nedaplatin; DDP: Cisplatin.

Table 4 Late adverse events in the two groups n (%)

Late adverse event	NDP group	DDP group	χ2	P value
Late esophageal injury
0	18 (52.9)	13 (38.2)
I	10 (29.4)	12 (35.3)
II	4 (11.8)	5 (14.7)	2.299	0.681
III	2 (5.9)	3 (8.8)
IV	0 (0)	1 (2.9)
Late lung injury
0	24 (70.6)	20 (58.8)
I	7 (20.6)	8 (23.5)
II	2 (5.9)	4 (11.8)	1.43	0.698
III	1 (2.9)	2 (5.9)
IV	0 (0)	0 (0)

NDP: Nedaplatin; DDP: Cisplatin.